454 M. S.
IYIKESICI
[66] Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane
transport of methotrexate by cultured human breast cancer cells.
Biochem Pharmacol. 1981;30:1537–1542.
[67] Gasparro FP, Krobler RM, Yemul SS, et al. Receptor-mediated
photo-cytotoxicity: synthesis of a photoactivatable psoralen
derivative conjugated to insulin. Biochem Biophys Res Commun.
1986;141:502–509.
[68] Yoshimasa Y, Namba Y, Hanaoka M, et al. A new approach to the
detection of autoantibodies against insulin receptors that inhibit
the internalization of insulin into human cells. Diabetes. 1984;33:
1051–1054.
[69] Poznansky MJ, Singh R, Singh B, et al. Insulin: carrier potential for
enzyme and drug therapy. Science. 1984;223:1304–1306.
[70] Jeffcoat R. The biosynthesis of unsaturated fatty acids and its
control in mammalian liver. Essays Biochem. 1979;15:1–36.
[71] Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor
content in human breast cancer. J Clin Invest. 1990;86:
1503–1510.
[72] Yee D. The insulin-like growth factors and breast cancer-revisited.
Breast Cancer Res Treat. 1998;47:197–199.
[73] Gross GE, Boldt DH, Osborne CK. Perturbation by insulin of
human breast cancer cell cycle kinetics. Cancer Res. 1984;44:
3570–3575.
[74] Toth C, Clemens Z. Halted progression of soft palate cancer in a
patient treated with the paleolithic ketogenic diet alone: a 20-
months follow-up. Am J Med Case Rep. 2016;4:288–292.
[75] Schmidt M, Pfetzer N, Schwab M, et al. Effects of a ketogenic diet
on the quality of life in 16 patients with advanced cancer: a pilot
trial. Nutr Metab (Lond). 2011;8:54.
[76] Rieger J, Bahr O, Maurer GD, et al. ERGO: a pilot study of keto-
genic diet in recurrent glioblastoma. Int J Oncol. 2014;44:
1843–1852.
[77] Seyfried TN. Case studies and personal experiences in using the
ketogenic diet for cancer management, in cancer as a metabolic
disease: on the origin, management and prevention of cancer.
Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2012.
[78] Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. Targeting insulin
inhibition as a metabolic therapy in advanced cancer: a pilot
safety and feasibility dietary trial in 10 patients. Nutrition. 2012;
28:1028–1035.
[79] Champ CE, Palmer JD, Volek JS, et al. Targeting metabolism with
a ketogenic diet during the treatment of glioblastoma multi-
forme. J Neurooncol. 2014;117:125–131.
[80] Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, et al.
Ketone body utilization drives tumor growth and metastasis. Cell
Cycle. 2012;11:3964–3971.
[81] Martinez-Outschoorn UE, Prisco M, Ertel A, et al. Ketones and lac-
tate increase cancer cell "stemness," driving recurrence, metasta-
sis and poor clinical outcome in breast cancer: achieving
personalized medicine via Metabolo-Genomics. Cell Cycle. 2011;
10:1271–1286.
[82] Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and
lactate "fuel" tumor growth and metastasis: evidence that epithe-
lial cancer cells use oxidative mitochondrial metabolism. Cell
Cycle. 2010;9:3506–3514.
[83] Tisdale MJ, Brennan RA. Loss of acetoacetate coenzyme A trans-
ferase activity in tumours of peripheral tissues. Br J Cancer. 1983;
47:293–297.
[84] Sawai M, Yashiro M, Nishiguchi Y, et al. Growth-inhibitory effects
of the ketone body, monoacetoacetin, on human gastric cancer
cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) defi-
ciency. Anticancer Res. 2004;24:2213–2217.
[85] Maurer GD, Brucker DP, Bahr O, et al. Differential utilization of
ketone bodies by neurons and glioma cell lines: a rationale for
ketogenic diet as experimental glioma therapy. BMC Cancer.
2011;11:315.
[86] Skinner R, Trujillo A, Ma X, et al. Ketone bodies inhibit the viabil-
ity of human neuroblastoma cells. J Pediatr Surg. 2009;44:
212–216. discussion 216.
[87] Klement RJ, Champ CE, Otto C, et al. Anti-tumor effects of keto-
genic diets in mice: a meta-analysis. PLoS One. 2016;11:e0155050.
[88] Magee BA, Potezny N, Rofe AM, et al. The inhibition of malignant
cell growth by ketone bodies. Aust J Exp Biol Med Sci. 1979;57:
529–539.
[89] Poff AM, Ari C, Arnold P, et al. Ketone supplementation decreases
tumor cell viability and prolongs survival of mice with metastatic
cancer. Int J Cancer. 2014;135:1711–1720.
[90] Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet
is an effective adjuvant to radiation therapy for the treatment of
malignant glioma. PLoS One. 2012;7:e36197.
[91] Schwartz K, Chang HT, Nikolai M, et al. Treatment of glioma
patients with ketogenic diets: report of two cases treated with an
IRB-approved energy-restricted ketogenic diet protocol and
review of the literature. Cancer Metab. 2015;3:3.
[92] Woolf EC, Scheck AC. The ketogenic diet for the treatment of
malignant glioma. J Lipid Res. 2015;56:5–10.
[93] Seyfried TN, Yu G, Maroon JC, et al. Press-pulse: a novel thera-
peutic strategy for the metabolic management of cancer. Nutr
Metab (Lond). 2017;14:19.